Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety
and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a …

OBJECTIVE The benefits of GH replacement in GH‐deficient adult patients are becoming
accepted but the safety profile continues to be defined. The GH deficiency in adults may …

Treatment of naive children with GH deficiency has relied upon long-term replacement
therapy with daily injections of GH. The daily schedule may be inconvenient for patients and …

Abstract Background: Between 1985 and 2006, the National Cooperative Growth Study
(NCGS) monitored the safety and efficacy of recombinant human growth hormone (rhGH) in …

Abstract The European Society for Paediatric Endocrinology held a consensus workshop in
Manchester, UK in December 2003 to discuss issues relating to the care of GH-treated …

GH treatment in adults with GH deficiency has numerous beneficial effects, but most studies
have been small. We report the results of an Australian multicenter, randomized, double …

OBJECTIVE Previous studies of GH replacement in adults have used unselected cohorts of
GH deficient (GHD) adults and weight‐based dosing regimens resulting in …

Abstract Objective The GH Research Society held a Consensus Workshop in Sydney,
Australia, 2007 to incorporate the important advances in the management of GH deficiency …

Background The beneficial effects of recombinant human GH (rhGH) therapy in GH deficient
(GHD) adults are well-established in the short term. However, data documenting the effects …

Until the advent of modern neuroradiological imaging techniques in 1989, a diagnosis of GH
deficiency in adults carried little significance other than as a marker of hypothalamo-pituitary …